Austin Doyle

2.0k total citations
33 papers, 1.0k citations indexed

About

Austin Doyle is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Austin Doyle has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Austin Doyle's work include PI3K/AKT/mTOR signaling in cancer (4 papers), Neuroblastoma Research and Treatments (4 papers) and Protein Degradation and Inhibitors (4 papers). Austin Doyle is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (4 papers), Neuroblastoma Research and Treatments (4 papers) and Protein Degradation and Inhibitors (4 papers). Austin Doyle collaborates with scholars based in United States, Finland and Sweden. Austin Doyle's co-authors include Adi F. Gazdar, James L. Mulshine, SE Martin, Martin Wj, Frank Cuttitta, Ilona Linnoila, P A Bunn, Keiko Funa, D Carney and Mark J. Krasna and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Austin Doyle

33 papers receiving 994 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Austin Doyle United States	15	423	413	311	215	112	33	1.0k
Marc Ballas United States	14	554 1.3×	254 0.6×	336 1.1×	144 0.7×	55 0.5×	46	905
Delicia Carey United States	15	596 1.4×	491 1.2×	242 0.8×	139 0.6×	85 0.8×	21	1.2k
Huiying Piao United States	10	442 1.0×	715 1.7×	198 0.6×	98 0.5×	125 1.1×	10	1.2k
Anna Novarino Italy	19	577 1.4×	294 0.7×	111 0.4×	319 1.5×	91 0.8×	43	1.1k
Bin Meng China	18	334 0.8×	245 0.6×	186 0.6×	136 0.6×	152 1.4×	62	814
Ladan Fazlollahi United States	9	324 0.8×	395 1.0×	269 0.9×	96 0.4×	112 1.0×	21	1.2k
Amélie Boichard United States	15	550 1.3×	311 0.8×	310 1.0×	123 0.6×	94 0.8×	25	1.0k
R. Stahel Switzerland	18	582 1.4×	447 1.1×	369 1.2×	243 1.1×	32 0.3×	68	1.2k
Carlynn Willmore‐Payne United States	15	414 1.0×	360 0.9×	328 1.1×	77 0.4×	146 1.3×	30	832

Countries citing papers authored by Austin Doyle

Since Specialization

Citations

This map shows the geographic impact of Austin Doyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Austin Doyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Austin Doyle more than expected).

Fields of papers citing papers by Austin Doyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Austin Doyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Austin Doyle. The network helps show where Austin Doyle may publish in the future.

Co-authorship network of co-authors of Austin Doyle

This figure shows the co-authorship network connecting the top 25 collaborators of Austin Doyle. A scholar is included among the top collaborators of Austin Doyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Austin Doyle. Austin Doyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Das, Satya, Jennifer G. Whisenant, Austin Doyle, Carmen J. Allegra, & Jordan Berlin. (2019). A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) [NCT03641313].. Journal of Clinical Oncology. 37(4_suppl). TPS175–TPS175. 1 indexed citations

Gross, Andrea M., Pamela L. Wolters, Andrea Baldwin, et al.. (2018). SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology. 36(15_suppl). 10503–10503. 31 indexed citations

Gross, Andrea M., Pamela L. Wolters, Andrea Baldwin, et al.. (2018). NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN). Neuro-Oncology. 20(suppl_2). i143–i144. 7 indexed citations

Kiesel, Brian F., Robert A. Parise, Liza C. Villaruz, et al.. (2017). LC–MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 146. 244–250. 5 indexed citations

Cynthia, X., César Sánchez, Feng Gao, et al.. (2016). A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer. Clinical Cancer Research. 22(11). 2650–2658. 62 indexed citations

Deming, Dustin A., Ludimila Cavalcante, Sam Joseph Lubner, et al.. (2015). A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Investigational New Drugs. 34(2). 168–175. 44 indexed citations

Webster, Jonathan, Raoul Tibes, Amanda L. Blackford, et al.. (2015). Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia. Blood. 126(23). 2563–2563. 2 indexed citations

Ahn, Daniel H., Junan Li, Lai Wei, et al.. (2015). Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Scientific Reports. 5(1). 12122–12122. 60 indexed citations

Wagner, Lars M., Maryam Fouladi, Atif Ahmed, et al.. (2014). Phase II trial of cixutumumab in combination with temsirolimus in pediatric patients with recurrent or refractory sarcoma: A report from the Children’s Oncology Group.. Journal of Clinical Oncology. 32(15_suppl). 10066–10066. 1 indexed citations

10.

Holkova, Beata, Jeffrey G. Supko, Matthew M. Ames, et al.. (2013). A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. Clinical Cancer Research. 19(7). 1873–1883. 26 indexed citations

11.

Naing, Aung, Patricia LoRusso, Vivek Subbiah, et al.. (2012). Abstract LB-124: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Cancer Research. 72(8_Supplement). LB–124. 1 indexed citations

12.

Chuang, Ellen, Paul J. Christos, Romain Kessler, et al.. (2010). Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Annals of Oncology. 21(10). 2075–2080. 10 indexed citations

13.

Ramaswamy, Bhuvaneswari, Mitch A. Phelps, Robert A. Baiocchi, et al.. (2010). A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Investigational New Drugs. 30(2). 629–638. 24 indexed citations

14.

Regine, William F., Nader Hanna, Michael Garofalo, et al.. (2007). Low-Dose Radiotherapy as a Chemopotentiator of Gemcitabine in Tumors of the Pancreas or Small Bowel: A Phase I Study Exploring a New Treatment Paradigm. International Journal of Radiation Oncology*Biology*Physics. 68(1). 172–177. 35 indexed citations

15.

Hamilton, James P., Fumiaki Sato, Bruce D. Greenwald, et al.. (2006). Promoter Methylation and Response to Chemotherapy and Radiation in Esophageal Cancer. Clinical Gastroenterology and Hepatology. 4(6). 701–708. 65 indexed citations

16.

Sonett, Joshua, Mohan Suntharalingam, Martin J. Edelman, et al.. (2004). Pulmonary Resection After Curative Intent Radiotherapy (>59 Gy) and Concurrent Chemotherapy in Non–Small-Cell Lung Cancer. The Annals of Thoracic Surgery. 78(4). 1200–1205. 117 indexed citations

17.

Jiao, Xiaolong, Mark J. Krasna, Joshua Sonett, et al.. (2001). Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer. European Journal of Cardio-Thoracic Surgery. 19(6). 880–886. 13 indexed citations

18.

Carney, Desmond N., Jonas Bergh, Austin Doyle, et al.. (1989). Biological response modifiers in the management of small cell lung cancer: a consensus report. Lung Cancer. 5(4-6). 143–145. 1 indexed citations

19.

Funa, Keiko, Adi F. Gazdar, K. Mattson, et al.. (1986). Interferon-mediated in vivo induction of β2-microglobulin on small-cell lung cancers and mid-gut carcinoids. Clinical Immunology and Immunopathology. 41(1). 159–164. 19 indexed citations

20.

Doyle, Austin, Martin Wj, Keiko Funa, et al.. (1985). Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.. The Journal of Experimental Medicine. 161(5). 1135–1151. 324 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact